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Abstract 
Background: Langerhans cell histiocytosis (LCH) is a disease that often affects children, but can also occur in adults 
and smokers. Oral manifestations are unusual and are characterized by bone pain, tooth mobility, necrotic ulcers and 
local edema. The aim of this paper is to describe a clinical case of LCH in an oral cavity that mimicked oral squamous 
cell carcinoma.
Case presentation: A male, 63 years old, complaining about a “wound in the mouth” for 6 months, without any pain 
or spontaneous bleeding. His medical history was free of disease. The patient was a smoker for 33 years. Intraoral 
examination revealed a destructive ulcerative lesion around the upper left first and second molars that resembled an 
oral squamous cell carcinoma. Biopsy of the ulcerative lesion was performed and the microscopic features showed 
an inflammatory infiltrate rich in plasma cells. Based on this microscopical finding, the final diagnosis was periodontal 
disease associated with a proliferative non-neoplastic lesion. The patient was referred to a specialized dental surgeon 
and underwent periodontal therapy including surgical procedures. After that, according to follow-up with the patient, 
there were no signs of disease remission. The lesion increased in size, although the patient did not complain of any 
symptoms. A second biopsy was performed and the microscopic features again showed a rich inflammatory infiltrate 
with mononuclear cells and histiocytic cells, characterized by pale histiocytes with lobed nuclei, resembling a bean. A 
varying number of eosinophils also were observed, without any evidence of atypical cells present in this infiltrate. An 
immunohistochemical staining panel was done to determine the nature of this inflammatory infiltrate by using anti-
bodies S-100, CD1a, CD-68 and CD45RO that were positive. These immunohistochemical findings were fundamental 
for the final diagnosis of LCH. The treatment included surgical extraction of all superior teeth, radiation and systemic 
corticoid therapies. After 8 years of treatment, the patient is free of disease.
Conclusion: Although LCH is an unusual lesion in an oral cavity, it can be present. Biopsy and a histological exam 
are essential to establish the diagnosis. Immunohistochemicals were fundamental to exclude malignant lesion and to 
confirm the diagnosis of LCH.
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Background
Langerhans cell histiocytosis (LCH) is a disease caused 
by the accumulation and proliferation of abnormal 
bone marrow-derived Langerhans cells. These dendritic 
cells, lymphocytes, eosinophils and non-dendritic his-
tiocytes form the typical infiltrates of LCH. These cells 
may be found at different degrees in several organs [1]. 
The Histiocyte Society proposed the reclassification of 
histiocytoses after the advent of ultrastructural stud-
ies and immunohistochemical staining [2, 3]. Moreover, 
proinflammatory cytokines and chemokines play a role 
in LCH, which suggests that it is an immune disorder. 
However, the detection of the oncogenic BRAF muta-
tion in more than half of LCH patients suggests that it is 
a neoplastic disorder [4]. The occurrence of LCH in an 
oral cavity is rare; however, there are reports of LCH in 
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oral mucosa and the most common site in the oral cav-
ity of adults is the jaw [3, 4]. The purpose of this paper is 
to describe a rare case of LCH located in upper maxilla 
and upper oral mucosa. The clinical findings and the his-
tological criteria were enabled to establish the final diag-
nosis of LCH, excluding periodontitis and carcinomatous 
lesion, and are presented and discussed.
Case presentation
A 63-year-old male complaining about a “wound in the 
mouth” was referred to Goiás Oral Medicine Center, Fed-
eral University of Goiás Dental School, Goiânia, Brasil, 
for diagnosis and treatment. The patient reported that 
the lesion had approximately 6 months of evolution and 
that he was asymptomatic and had not experienced any 
bleeding. His medical and dental history did not show 
any significance or any relation to his lesion. The patient 
had been a smoker for 33  years. Intraoral examina-
tion revealed a destructive ulcerative lesion around the 
upper left first and second molars, which showed mobil-
ity and poor dental conditions, including dental caries, 
gingival recession and bone loss (Fig.  1a). A panoramic 
radiograph revealed a radiolucent area in the periapical 
region of the upper left first molar, suggesting an osteo-
lytic lesion (Fig. 1b). According to the clinical and radi-
ographic features, the main diagnostic hypotheses were 
periodontal disease associated with oral squamous cell 
carcinoma. The patient reported that there was no can-
cer in his family history. The results of laboratory analy-
ses, including blood and urine studies, were within the 
normal range. We also performed a biopsy to provide 
histopathological analysis. At this time, the patient took 
prescribed antibiotics for 7 days and underwent surgery 
of the upper left primary molar. Microscopic findings 
showed an inflammatory infiltrate rich in plasma cells 
that is commonly present in periodontal disease, without 
the presence of any atypical cell in this specimen of oral 
mucosa. Based on these findings, periodontal disease was 
considered as the diagnosis and the patient underwent 
periodontal therapy twice without remission of the initial 
injury. During follow-up, it was observed that the lesion 
increased considerably.
Since the lesion was increasing in size, a second biopsy 
was performed on a deeper level of histological plan. It 
showed a proliferation of cells resembling histiocytes 
with an occasional pale nucleus edentulous with a lobu-
lar, grain bean-like appearance (Fig.  2). Microscopic 
findings and the presence of histiocytic cells led to the 
performance of an immunohistochemical staining panel 
using monoclonal antibodies for S-100 (Fig.  3a), CD1a 
(Fig.  3b), pan-cytokeratin, CD-68, melanoma marker 
(HMB45) and melanoma A protein. There was posi-
tivity for S-100, CD1a, CD-68 and CD45RO (Table  1). 
Immunohistochemical analysis led to the diagnosis of 
LCH. We performed a complete investigation, including 
bone scintigraphy bone, abdomen CT scan; hematologi-
cal exams, including blood glucose (due to diabetes risk) 
and a pathological analysis of bone marrow, which was 
hypercellular without evidence of atypical cells. The liver, 
spleen and lymph nodes were free of disease. There was 
no bone involvement besides upper maxilla. The treat-
ment included surgical extraction of all superior teeth, 
due their periodontal involvement, radiation therapy, 
corticoid therapies and prosthesis. An established radia-
tion protocol of 26 Gy fractionated over 13 sessions was 
instituted and well tolerated. We have been following up 
with the patient for 8 years (2006–2014) without signs of 
disease recurrence (Fig. 4a and b). At the last follow-up, 
the patient was considered “disease-free”. Hematological 
exams, as well as abdomen and chest exams, showed nor-
mal conditions.
Discussion
Histiocytosis comprises a diverse group of prolifera-
tive disorders characterized by the infiltration and accu-
mulation of histiocytes and other immune effector cells 
Fig. 1 Intraoral (a) and panoramic radiograph (b) showed a lesion around the upper left first and second molars
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within various tissues [2]. Historically, the nomencla-
ture regarding this entity has been confused. The disease 
had been subcategorized based upon different clinical 
manifestations, such as Histiocytosis X, Letterer-Siwe 
disease, Hand-Schuller-Christian syndrome and Eosino-
philic Granuloma of bone. The Histiocyte Society pro-
posed the reclassification of histiocytosis based upon 
the predominant cell type within the infiltrate. The clas-
sification system includes four divisions: dendritic dis-
orders (including LCH), macrophage-related disorders, 
malignant histiocytic disorders and dendritic cell or 
macrophage-related histiocytic sarcoma [2, 3]. The LCH 
etiology has been discussed for many years and its reac-
tive nature is suggested. Clonal proliferation has been 
reported with the presence of BRAF V600E oncogenic 
mutation in more than half of patients with LCH, which 
Fig. 2 Hematoxylin-eosin staining showed basophilic nuclei and 
eosinophilic cell plasma
Fig. 3 Immunohistochemical staining showed cells positive for S-100 protein (a) and CD1a protein (b)
Table 1 Immunohistochemical panel of monoclonal antibodies used in this study
+ Positivity
− Negative
Antigen Antibody Dilution Specificity Results
S-100 Lyophilized polyclonal, biocare 1:400 Langerhans cells, cells of the peripheral nervous 
system, melanocytes and tumor cells derived 
from these cell lines
+
CD1a Monoclonal, novocastra 1:600 Langerhans cells, cell surfaces of cortical thymo-
cytes and interdigitating dendritic cells
+
CD-68 Monoclonal mouse antibody specificity for 
human CD-68 antigen, dako
1:10,000 Langerhans cells, mononuclear phagocyte 
system
+
CD45RO Monoclonal mouse antibody specificity for 
human CD45RO antigen, dako
1:800 T lymphocytes, CD4 lymphocytes and thymo-
cytes
+
Pan-cytokeratin Monoclonal mouse antibody anti-human 
cytokeratin, novocastra
1:400 Human cytokeratin human, identification of cells 
of simple and stratified epithelial origin
−
Melanoma marker (HMB45) Lyophilized monoclonal novocastra 1:200 Retinal epithelium, melanocytes and non-mel-
anocytic cells
−
Melanina A Lyophilized monoclonal; novocastra 1:200 Cytotoxic T lymphocytes −
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suggests a neoplasm [4, 6]. LCH is a rare disease with a 
wide variety of clinical presentations. Its course may 
damage different tissues, including the periodontal bone 
and gingiva. In addition, one of the types of LCH can 
lead to death [4, 5]. In our specific case, the patient had 
a lesion that mimicked periodontal disease associated 
with an oral squamous cell carcinoma or carcinomatous 
lesion.
LCH in adults has been reported at an incidence of 
1:1,000,000 and a mean age of presentation of 34  years 
and is usually a multisystem disease. Childhood LCH 
has a reported incidence of 1:200,000, peaking between 
ages 1–4 years [3, 6]. In children, an association between 
high concentrations of salivary IL-1 β and PGE(2) and 
advanced stages of LCH have been observed, suggesting 
that the abnormal amount of these factors in the saliva 
may be a risk marker for disease progression [7].
Our case was distinct to most reported cases in the 
literature, since the patient was a 63-year-old man who 
did not show any bone or organ involvement other than 
the maxilla. Despite the strong possibility of pulmonary 
manifestation, due to the duration time of time that he 
had been a smoker, there was no evidence of pulmo-
nary involvement. The chest x-ray confirmed this fact. 
However, experimental studies have shown that ciga-
rette exposure is associated with pulmonary inflamma-
tion [8]. Interestingly, most LCH bone lesions that have 
been described in the literature were present in the skull, 
spine, or mandible [9]. In our case, the lesion was located 
only in the maxilla. Bone scintigraphy was determinant 
to show the unique bony involvement.
Diabetes insipidus (DI) is the most common endocrine 
abnormality, reported in 5–50  % of patients with LCH. 
DI is a result of the destruction of more than 80 % of the 
paraventricular-supraoptic neurons [10, 11]. Despite the 
high frequency of DI reported in prior literature, in our 
case, all hematological and biochemical parameters, liver 
function tests, urine osmolarity and endocrine evalua-
tions were within the normal limits.
It is essential to note that the clinical and radiographic 
presentation of LCH could mimic an acute or chronic 
periodontal or periapical lesion, radicular cysts, osteo-
myelitis and malignancies. The lesions often appear as 
sharply punched-out radiolucent images, and the teeth 
appear to be “floating” when extensive alveolar involve-
ment occurs [12]. Professionals should consider LCH as 
a possible diagnosis in different situations: periodontal 
lesions recurrent after conventional treatment, the pres-
ence of systemic symptoms previously mentioned and 
associated with periodontal lesions and after rapid, severe 
and localized periodontal bone loss. In this specific case, 
the lesion resembled a periodontal lesion associated with 
a carcinomatous lesion; however, the histological findings 
did not show any evidence of neoplastic cells.
The presence of pale histiocytes was fundamental to 
decide to do an immunohistochemical panel to inves-
tigate the nature of these cells. Monoclonal antibodies 
for S-100 (Fig. 3a), CD1a pan-cytokeratin, CD-68, mela-
noma marker (HMB45) and melanoma A protein were 
included in this panel. Positive staining for S-100, CD1a, 
and CD-68 established the final diagnosis in our case. 
The CD1a marker is essential for distinguishing Langer-
hans cells from other dentritic cells and histiocytes [13]. 
In our case, this additional examination by immunohis-
tochemical techniques was critical for the establishment 
of the correct diagnosis of LCH and treatment planning 
for the patient.
The first step for the treatment of LCH should be to 
determine the number of organ systems involved. Then 
patients who have single-system disease should be sub-
categorized based on the number of sites involved. The 
presence or absence of organ dysfunction is a subcat-
egory for patients who have multi-organ disease [14–18]. 
Curettage is generally sufficient for patients with local-
ized bone lesions. However, it also possible to employ 
intralesional steroids or low-dose radiation. Treatment of 
multiorgan disease is controversial. Some state that high-
dose prednisone should be the first-line therapy, whereas 
Fig. 4 Intraoral (a) view and panoramic radiograph (b) showed no bone disease (8 years later during follow-up)
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others suggest the use of single-agent chemotherapy [3, 
14–17]. A combination of vinblastine and prednisone 
is an effective therapy used as the standard regimen 
for multisystem LCH in children and should be further 
explored in adult patients [18]. Other treatments, such 
as targeted therapy with BRAF inhibitors, has been used 
in select patients with encouraging results [18]. Another 
model indicates both BRAF mutation and IL-1 loop regu-
lation as potential LCH therapeutic targets [19].
In our case, the patient underwent surgical extraction 
of all superior teeth, due to their periodontal involve-
ment; curettage of the bone lesion; local radiation and 
corticoid therapies and prosthesis. The prognosis of LCH 
depends on the number of organs involved, as well as 
the presence of organ dysfunction and, in minors, on the 
age of the patient at the disease onset [4, 14–18]. In this 
specific case reported, the prognosis was favorable, due 
to single bone involvement, early diagnosis and proper 
treatment. Moreover, the patient had no signs of recur-
rence after 8 years of follow-up.
Final considerations
In summary, we reported an unusual case of LCH in an 
elderly male patient who had a unique oral manifesta-
tion. LCH is a disease with a wide spectrum of clinical 
manifestations and a definitive diagnosis relies on biopsy 
and immunohistochemical examinations. It is extremely 
important that the doctor or dentist perform the correct 
diagnosis to plan the most appropriate treatment, since 
LCH clinically resembles other diseases that are treated 
differently. Moreover, the wrong diagnosis and treatment 
may compromise the patient’s life.
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LCH: langerhans cell histiocytosis.
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